Product Pipeline

On March 27, 2025, Suraxavir Marboxil Tablets (brand name: Yisuda) received marketing approval from the National Medical Products Administration (NMPA). It is indicated for the treatment of uncomplicated influenza A and B in previously healthy adolescents and adults aged 12 and older.

Phase III clinical trial data were published in the prestigious global medical research journal Nature Medicine.

Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Nature Medicine, 2025 Jan 7.
doi: 10.1038/s41591-024-03419-3

ClinicalTrials.gov registration: NCT05474755.

Aurantii Fructus Immaturus Total Flavonoids Tablet (Brand name: Orante) is an innovative Class 1.2 traditional Chinese medicine developed by Qingfeng Pharmaceutical. The main ingredient is total flavonoid extract of Aurantii Fructus Immaturus, used for functional dyspepsia.

The two Phase III clinical trials (placebo-controlled and compared with Domperidone) show that Aurantii Fructus Immaturus Total Flavonoids Tablet have good therapeutic effects on common symptoms of functional dyspepsia (such as liver-stomach disharmony, spleen-stomach damp-heat, food stagnation, and spleen-stomach deficiency). The trials also showed that symptom relief persisted after discontinuation, with a better safety profile and sustained efficacy than the active comparator drug.